Genaissance starts STRENGTH II

GNSC said it will start a second STRENGTH (Statin Response Examined by Genetic HAP Markers) trial, designed to link clinical response to Mevacor lovastatin from Merck (MRK) with GNSC's haplotype (HAP) Markers. The U.S. trial will enroll 150 volunteers with Type IIa or IIb hypercholesterolemia. Patients will be treated for 8 weeks at the recommended starting dose of lovastatin, and for another 8 weeks at the highest allowed dose. Data are expected in the third quarter of next year. ...